{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T19:02:26Z","timestamp":1771786946335,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation of China","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-37607-7","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T14:34:51Z","timestamp":1770129291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bronchial artery infusion of PD-1 inhibitors plus chemotherapy improves progression-free survival in advanced NSCLC: a prospective cohort study"],"prefix":"10.1038","volume":"16","author":[{"given":"Bin","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaocheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanchao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuliang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"37607_CR1","doi-asserted-by":"publisher","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 74, 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","DOI":"10.3322\/caac.21834"},{"key":"37607_CR2","doi-asserted-by":"publisher","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. Cancer J. Clin. 74, 12\u201349. https:\/\/doi.org\/10.3322\/caac.21820 (2024).","DOI":"10.3322\/caac.21820"},{"key":"37607_CR3","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-Positive Non-Small-Cell lung cancer. N Engl. J. Med. 375, 1823\u20131833. https:\/\/doi.org\/10.1056\/NEJMoa1606774 (2016).","journal-title":"N Engl. J. Med."},{"key":"37607_CR4","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer, R. J. et al. Nivolumab versus everolimus in advanced Renal-Cell carcinoma. N Engl. J. Med. 373, 1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665 (2015).","journal-title":"N Engl. J. Med."},{"key":"37607_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi, M. et al. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol. Cancer. 21, 28. https:\/\/doi.org\/10.1186\/s12943-021-01489-2 (2022).","journal-title":"Mol. Cancer"},{"key":"37607_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","volume":"1248","author":"L Ai","year":"2020","unstructured":"Ai, L., Xu, A. & Xu, J. Roles of PD-1\/PD-L1 pathway: Signaling, cancer, and beyond. Adv. Exp. Med. Biol. 1248, 33\u201359. https:\/\/doi.org\/10.1007\/978-981-15-3266-5_3 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"37607_CR7","doi-asserted-by":"publisher","unstructured":"Horn, L. et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, trials (CheckMate 017 and CheckMate 057). J. Clin. Oncol. 35, 3924\u20133933. https:\/\/doi.org\/10.1200\/jco.2017.74.3062 (2017).","DOI":"10.1200\/jco.2017.74.3062"},{"key":"37607_CR8","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/s0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip, E. et al. Adjuvant Atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet (London England). 398, 1344\u20131357. https:\/\/doi.org\/10.1016\/s0140-6736(21)02098-5 (2021).","journal-title":"Lancet (London England)"},{"key":"37607_CR9","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/jco.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck, M. et al. Five-Year outcomes with pembrolizumab versus chemotherapy for metastatic Non-Small-Cell lung cancer with PD-L1 tumor proportion Score\u2009\u2265\u200950. J. Clin. Oncol. 39, 2339\u20132349. https:\/\/doi.org\/10.1200\/jco.21.00174 (2021).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"key":"37607_CR10","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1200\/jco.20.01605","volume":"39","author":"H Borghaei","year":"2021","unstructured":"Borghaei, H. et al. Five-Year outcomes from the Randomized, phase III trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated Non-Small-Cell lung cancer. J. Clin. Oncol. 39, 723\u2013733. https:\/\/doi.org\/10.1200\/jco.20.01605 (2021).","journal-title":"J. Clin. Oncology: Official J. Am. Soc. Clin. Oncol."},{"key":"37607_CR11","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","volume":"27","author":"JM Kim","year":"2016","unstructured":"Kim, J. M. & Chen, D. S. Immune escape to PD-L1\/PD-1 blockade: seven steps to success (or failure). Annals Oncology: Official J. Eur. Soc. Med. Oncol. 27, 1492\u20131504. https:\/\/doi.org\/10.1093\/annonc\/mdw217 (2016).","journal-title":"Annals Oncology: Official J. Eur. Soc. Med. Oncol."},{"key":"37607_CR12","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/s0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet (London England). 387, 1540\u20131550. https:\/\/doi.org\/10.1016\/s0140-6736(15)01281-7 (2016).","journal-title":"Lancet (London England)"},{"key":"37607_CR13","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/s0140-6736(18)32409-7","volume":"393","author":"TSK Mok","year":"2019","unstructured":"Mok, T. S. K. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet (London England). 393, 1819\u20131830. https:\/\/doi.org\/10.1016\/s0140-6736(18)32409-7 (2019).","journal-title":"Lancet (London England)"},{"key":"37607_CR14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00262-021-03045-9","volume":"71","author":"M Russano","year":"2022","unstructured":"Russano, M. et al. Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1\/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunol. Immunotherapy: CII. 71, 865\u2013874. https:\/\/doi.org\/10.1007\/s00262-021-03045-9 (2022).","journal-title":"Cancer Immunol. Immunotherapy: CII"},{"key":"37607_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.14059","author":"M Kitano","year":"2024","unstructured":"Kitano, M. et al. Delayed immune-related adverse events in long-responders of immunotherapy: a single-center experience. Asia-Pac. J. Clin. Oncol. https:\/\/doi.org\/10.1111\/ajco.14059 (2024). ;20:463\u2009\u2013\u200971.","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"37607_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3757-7","author":"AF Alharbi","year":"2019","unstructured":"Alharbi, A. F. et al. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion. Cancer Chemother. Pharmacol. https:\/\/doi.org\/10.1007\/s00280-018-3757-7 (2019). ;83:387\u2009\u2013\u200991.","journal-title":"Cancer Chemother. Pharmacol."},{"key":"37607_CR17","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/bcp.13557","volume":"84","author":"EJB Derissen","year":"2018","unstructured":"Derissen, E. J. B. et al. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2\u2019,2\u2019-difluorodeoxyuridine and their nucleotides. Br. J. Clin. Pharmacol. 84, 1279\u20131289. https:\/\/doi.org\/10.1111\/bcp.13557 (2018).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"37607_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2018.08.022","author":"K Han","year":"2019","unstructured":"Han, K. et al. Bronchial artery embolization for hemoptysis in primary lung cancer: A retrospective review of 84 patients. J. Vascular Interventional Radiology: JVIR. https:\/\/doi.org\/10.1016\/j.jvir.2018.08.022 (2019). ;30:428\u2009\u2013\u200934.","journal-title":"J. Vascular Interventional Radiology: JVIR"},{"key":"37607_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12672-025-02398-2","volume":"16","author":"B Liu","year":"2025","unstructured":"Liu, B. et al. Safety of bronchial artery infusion immunotherapy: from comparative analysis in beagle canines to clinical validation. Discover Oncol. 16, 621. https:\/\/doi.org\/10.1007\/s12672-025-02398-2 (2025).","journal-title":"Discover Oncol."},{"key":"37607_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay3575","author":"DM Francis","year":"2020","unstructured":"Francis, D. M. et al. Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy. Sci. Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aay3575 (2020). ;12.","journal-title":"Sci. Transl Med."},{"key":"37607_CR21","doi-asserted-by":"publisher","unstructured":"Tang, S. et al. Immune checkpoint inhibitors in non-small cell lung cancer: Progress, challenges, and prospects. Cells 11 https:\/\/doi.org\/10.3390\/cells11030320 (2022).","DOI":"10.3390\/cells11030320"},{"key":"37607_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","volume":"22","author":"EP Darnell","year":"2020","unstructured":"Darnell, E. P. et al. Immune-Related adverse events (irAEs): Diagnosis, Management, and clinical pearls. Curr. Oncol. Rep. 22, 39. https:\/\/doi.org\/10.1007\/s11912-020-0897-9 (2020).","journal-title":"Curr. Oncol. Rep."},{"key":"37607_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032676","author":"E Blanco","year":"2023","unstructured":"Blanco, E. et al. Leading edge: intratumor delivery of monoclonal antibodies for the treatment of solid tumors. Int. J. Mol. sciences;24. https:\/\/doi.org\/10.3390\/ijms24032676 (2023).","journal-title":"Int. J. Mol. sciences;24"},{"key":"37607_CR24","doi-asserted-by":"publisher","first-page":"830631","DOI":"10.3389\/fimmu.2022.830631","volume":"13","author":"J Yin","year":"2022","unstructured":"Yin, J. et al. Checkpoint inhibitor pneumonitis induced by Anti-PD-1\/PD-L1 therapy in Non-Small-Cell lung cancer: occurrence and mechanism. Front. Immunol. 13, 830631. https:\/\/doi.org\/10.3389\/fimmu.2022.830631 (2022).","journal-title":"Front. Immunol."},{"key":"37607_CR25","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.21873\/anticanres.15929","volume":"42","author":"K Sakuma","year":"2022","unstructured":"Sakuma, K. et al. An in vivo study of local administration of Low-dose Anti-PD-1 antibody using an oral cancer cell line. Anticancer Res. 42, 4293\u20134303. https:\/\/doi.org\/10.21873\/anticanres.15929 (2022).","journal-title":"Anticancer Res."},{"key":"37607_CR26","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/1759-7714.13522","volume":"11","author":"B Shang","year":"2020","unstructured":"Shang, B. et al. Clinical effect of bronchial arterial infusion chemotherapy and callispheres drug-eluting beads in patients with stage II-IV lung cancer: A prospective cohort study. Thorac. Cancer. 11, 2155\u20132162. https:\/\/doi.org\/10.1111\/1759-7714.13522 (2020).","journal-title":"Thorac. Cancer"},{"key":"37607_CR27","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s11547-016-0629-2","volume":"121","author":"YF Fu","year":"2016","unstructured":"Fu, Y. F. et al. Transcatheter arterial chemical infusion for advanced non-small-cell lung cancer: long-term outcome and predictor of survival. Radiol. Med. 121, 605\u2013610. https:\/\/doi.org\/10.1007\/s11547-016-0629-2 (2016).","journal-title":"Radiol. Med."},{"key":"37607_CR28","doi-asserted-by":"publisher","first-page":"110747","DOI":"10.1016\/j.ejrad.2023.110747","volume":"161","author":"G He","year":"2023","unstructured":"He, G. et al. Bronchial artery chemoembolization with drug-eluting beads versus bronchial artery infusion followed by Polyvinyl alcohol particles embolization for advanced squamous cell lung cancer: A retrospective study. Eur. J. Radiol. 161, 110747. https:\/\/doi.org\/10.1016\/j.ejrad.2023.110747 (2023).","journal-title":"Eur. J. Radiol."},{"key":"37607_CR29","doi-asserted-by":"publisher","first-page":"1088274","DOI":"10.3389\/fbioe.2022.1088274","volume":"10","author":"X Ma","year":"2022","unstructured":"Ma, X. et al. Clinical outcomes of Vinorelbine loading callispheres beads in the treatment of previously treated advanced lung cancer with progressive refractory obstructive atelectasis. Front. Bioeng. Biotechnol. 10, 1088274. https:\/\/doi.org\/10.3389\/fbioe.2022.1088274 (2022).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"37607_CR30","doi-asserted-by":"publisher","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","volume":"13","author":"A Chennamadhavuni","year":"2022","unstructured":"Chennamadhavuni, A. et al. Risk factors and biomarkers for immune-Related adverse events: A practical guide to identifying High-Risk patients and rechallenging immune checkpoint inhibitors. Front. Immunol. 13, 779691. https:\/\/doi.org\/10.3389\/fimmu.2022.779691 (2022).","journal-title":"Front. Immunol."},{"key":"37607_CR31","doi-asserted-by":"publisher","unstructured":"Shankar, B. et al. Multisystem immune-Related adverse events associated with immune checkpoint inhibitors for treatment of Non-Small cell lung cancer. JAMA Oncol. 6, 1952\u20131956. https:\/\/doi.org\/10.1001\/jamaoncol.2020.5012 (2020).","DOI":"10.1001\/jamaoncol.2020.5012"},{"key":"37607_CR32","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille, C. et al. Immune checkpoint inhibitor Rechallenge after Immune-Related adverse events in patients with cancer. JAMA Oncol. 6, 865\u2013871. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0726 (2020).","journal-title":"JAMA Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37607-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37607-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37607-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T18:03:44Z","timestamp":1771783424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-37607-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["37607"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-37607-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7067"}}